JP6769992B2 - ポリマーナノ粒子における感光性化合物を含む組成物およびその組成物を使用する方法 - Google Patents

ポリマーナノ粒子における感光性化合物を含む組成物およびその組成物を使用する方法 Download PDF

Info

Publication number
JP6769992B2
JP6769992B2 JP2017555716A JP2017555716A JP6769992B2 JP 6769992 B2 JP6769992 B2 JP 6769992B2 JP 2017555716 A JP2017555716 A JP 2017555716A JP 2017555716 A JP2017555716 A JP 2017555716A JP 6769992 B2 JP6769992 B2 JP 6769992B2
Authority
JP
Japan
Prior art keywords
composition according
cancer
nanoparticles
sinc
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017555716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513875A5 (enExample
JP2018513875A (ja
Inventor
タラチュラ、オレナ
タラチュラ、オレフ
アラニ、アダム
Original Assignee
オレゴン ステート ユニヴァーシティ
オレゴン ステート ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ステート ユニヴァーシティ, オレゴン ステート ユニヴァーシティ filed Critical オレゴン ステート ユニヴァーシティ
Publication of JP2018513875A publication Critical patent/JP2018513875A/ja
Publication of JP2018513875A5 publication Critical patent/JP2018513875A5/ja
Application granted granted Critical
Publication of JP6769992B2 publication Critical patent/JP6769992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017555716A 2015-04-20 2016-04-18 ポリマーナノ粒子における感光性化合物を含む組成物およびその組成物を使用する方法 Active JP6769992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150125P 2015-04-20 2015-04-20
US62/150,125 2015-04-20
PCT/US2016/028113 WO2016172046A1 (en) 2015-04-20 2016-04-18 A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition

Publications (3)

Publication Number Publication Date
JP2018513875A JP2018513875A (ja) 2018-05-31
JP2018513875A5 JP2018513875A5 (enExample) 2019-06-06
JP6769992B2 true JP6769992B2 (ja) 2020-10-14

Family

ID=57144184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555716A Active JP6769992B2 (ja) 2015-04-20 2016-04-18 ポリマーナノ粒子における感光性化合物を含む組成物およびその組成物を使用する方法

Country Status (6)

Country Link
US (1) US10646472B2 (enExample)
EP (1) EP3285765B1 (enExample)
JP (1) JP6769992B2 (enExample)
CN (1) CN107613975B (enExample)
CA (1) CA2981614C (enExample)
WO (2) WO2016172046A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3285765B1 (en) * 2015-04-20 2020-04-08 Oregon State University A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition
CN107789623B (zh) * 2017-11-09 2020-12-15 福州大学 哌嗪取代硅酞菁及其在光热治疗中的应用
RU2020132481A (ru) * 2018-03-30 2022-05-04 Торэй Индастриз, Инк. Биоразлагаемый блок-сополимер
US20210268129A1 (en) * 2018-06-22 2021-09-02 The Governers Of The University Of Alberta Theranostic Radiophotodynamic Therapy Nanoparticles
JP7371476B2 (ja) * 2018-12-13 2023-10-31 東洋インキＳｃホールディングス株式会社 近赤外蛍光組成物および近赤外蛍光標識剤
WO2020132980A1 (zh) * 2018-12-26 2020-07-02 深圳先进技术研究院 细菌-光热纳米颗粒复合物及制备方法和应用
US20220211860A1 (en) * 2019-05-02 2022-07-07 The University Of Sydney Peptide derivatives and conjugates thereof for treating cancer
AU2021299343A1 (en) * 2020-06-30 2023-03-02 Kenvue Brands Llc Device and method for controlling treatment for a skin condition using a tracer
KR20230047155A (ko) 2020-08-03 2023-04-06 존슨 앤드 존슨 컨수머 인코포레이티드 눈밑 브라이트닝을 부여하기 위한 화장 조성물의 선택적 도포용 시스템 및 방법
CN112972690B (zh) * 2021-02-22 2022-12-23 上海交通大学医学院附属第九人民医院 一种基于三角纳米金载体、制备方法及用途
EP4066818B1 (en) * 2021-04-01 2023-11-29 Agfa-Gevaert Nv Near infrared absorbing composite resin particles
CN113368235B (zh) * 2021-05-11 2022-11-15 上海师范大学 一种Gd-NGQDs/BTS@PLGA-PEG纳米材料及其制备方法和应用
US20240424147A1 (en) * 2021-10-05 2024-12-26 The Trustees Of The University Of Pennsylvania Phthalocyanine-loaded micelles for the direct visualization of tumors
CN116637209B (zh) * 2023-05-18 2024-06-07 南京溯远基因科技有限公司 一种荧光染料复合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
JP2010083860A (ja) * 2008-02-29 2010-04-15 Kyoto Univ ポリマーナノ微粒子及び光分子イメージング用造影剤
IT1391530B1 (it) * 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
US9517277B2 (en) 2011-07-15 2016-12-13 University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
US8974830B2 (en) * 2012-02-23 2015-03-10 Canon Kabushiki Kaisha Particles and contrast agent including the same for optical imaging
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
WO2015026963A2 (en) * 2013-08-21 2015-02-26 Oregon State University Phthalocy anine-dendrimer compositions and a method of using
EP3285765B1 (en) * 2015-04-20 2020-04-08 Oregon State University A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy

Also Published As

Publication number Publication date
EP3285765A4 (en) 2018-12-05
WO2016172046A1 (en) 2016-10-27
WO2019079201A2 (en) 2019-04-25
WO2019079201A3 (en) 2019-05-31
EP3285765A1 (en) 2018-02-28
CA2981614C (en) 2023-09-05
EP3285765B1 (en) 2020-04-08
US10646472B2 (en) 2020-05-12
CA2981614A1 (en) 2016-10-27
CN107613975A (zh) 2018-01-19
JP2018513875A (ja) 2018-05-31
US20180028496A1 (en) 2018-02-01
CN107613975B (zh) 2021-08-03

Similar Documents

Publication Publication Date Title
US10646472B2 (en) Composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition
Xue et al. Porphyrin-based nanomedicines for cancer treatment
Itoo et al. Nanotherapeutic intervention in photodynamic therapy for cancer
Huang et al. Long wavelength single photon like driven photolysis via triplet triplet annihilation
Li et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy
AU2016358441B2 (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
JP5979385B2 (ja) リポソーム複合体
Ramírez-García et al. An immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer
CN109310702A (zh) 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
Hu et al. Post-synthesis strategy to integrate porphyrinic metal–organic frameworks with CuS NPs for synergistic enhanced photo-therapy
Thanasekaran et al. Lipid-wrapped upconversion nanoconstruct/photosensitizer complex for near-infrared light-mediated photodynamic therapy
WO2016061256A1 (en) Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
EP3508221A1 (en) Tumor-targeting photosensitizer-drug conjugate, method for preparing same and pharmaceutical composition for preventing or treating tumor containing same
WO2015026963A2 (en) Phthalocy anine-dendrimer compositions and a method of using
Sun et al. Highly efficient water-soluble photosensitizer based on chlorin: synthesis, characterization, and evaluation for photodynamic therapy
Kim et al. pH-Sensitive carbon dots for enhancing photomediated antitumor immunity
Celikbas et al. Image-guided enhanced PDT/PTT combination therapy using brominated hemicyanine-loaded folate receptor-targeting Ag2S quantum dots
Mu et al. Lighting up self-quenching nanoaggregates with protein corona for simultaneous intraoperative imaging and photothermal theranostics of metastatic cancer
Choi et al. Multi-shell structured upconversion nanocarriers that combine IDO inhibitor-induced immunotherapy with NIR-triggered photodynamic therapy for deep tumors
Yang et al. Multifunctional System with Camptothecin and [12] aneN3 Units for Effective In Vivo Anti Pancreatic Cancer through Synergistic Chemotherapy, Gene Therapy, and Photodynamic Therapy
EP2711366A1 (en) Cationic triphenylamine derivatives activable by visible and Infra Red light for inducing and imaging apoptosis in cancer cells
Wang et al. Dual pH-responsive polypeptide nanoprobes for lysosomes enhanced bioimaging and tumor photothermal therapy under 1064 nm irradiation
KR102822996B1 (ko) 디셀레나이드 함유 탄화수소를 포함하고 미토콘드리아 표적형 초음파감작제가 탑재된 ros/gsh 이중 감응성 세포 외 소포체 및 이를 이용한 초음파역학 치료제
McGonigal Aggregation-Induced Emission (AIE), Life and Health
CN117599214B (zh) 一种靶向碳酸酐酶的顺铂诊疗探针及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200924

R150 Certificate of patent or registration of utility model

Ref document number: 6769992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250